Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 2;4(8):e2119132.
doi: 10.1001/jamanetworkopen.2021.19132.

Exploration of Immune-Related Gene Expression in Osteosarcoma and Association With Outcomes

Wangmi Liu  1 , Xiankuan Xie  1 , Yiying Qi  1 , Jiayan Wu  2
Affiliations

Exploration of Immune-Related Gene Expression in Osteosarcoma and Association With Outcomes

Wangmi Liu et al. JAMA Netw Open. .

Abstract

Importance: Host immune dysregulation is associated with initiation and development of osteosarcoma. In addition, immunotherapy for osteosarcomas requires some knowledge of the immune state of patients.

Objective: To perform an immunogenomic landscape analysis based on The Cancer Genome Atlas (TCGA) project, which provides osteosarcoma samples with clinical information.

Design, setting, and participants: This genetic association study was conducted from July 20, 2020, to September 20, 2020, as a secondary analysis of public data. Cox regression and risk score analyses were used to construct signatures of immune-related genes (IRGs) in 84 patients with osteosarcoma from TCGA with corresponding clinical information. Patients were divided into high- and low-risk groups with 42 individuals in each group according to their risk scores. Data were analyzed from July 20 to September 20, 2020.

Main outcomes and measures: Differentially expressed genes (DEGs) were analyzed between groups, and potential molecular mechanisms, expression regulation, and immune cell infiltration were also explored using bioinformation methods. A prognostic model based on independent risk factors selected from multivariate Cox hazard ratio regression was established to estimate 1-year overall survival.

Results: In this genetic association study based on 84 samples from patients with osteosarcoma from TCGA (mean [SD] age, 15.0 [4.8] years; 47 [56.0%] men; mean [SD] follow-up time, 4.1 [2.8] years), a total of 14 survival-associated IRGs were identified. Patients assigned to the high-risk group had worse survival than patients from the low-risk group (1 death [2.4%] vs 26 deaths [61.9%%]; P < .001). The protein digestion and absorption pathway was one of the associated pathways in the functional enrichment analysis (gene ratio, 2:8; P < .001). The prognostic model based on metastases at diagnosis and risk score performed well in 1-year overall survival estimations (area under the curve, 0.947; 95% CI, 0.832-0.972). The risk score was correlated with immune cell infiltration (B cells: r = 0.331; P = .002; macrophages: r = 0.410; P < .001; CD8 T cells: r = 0.230; P = .04).

Conclusions and relevance: This genetic association study developed a prognostic modeling tool for osteosarcoma based on IRG expression profiles, which could result in improved survival rates through more individualized therapies. Further research on IRG expression profiles could provide potential targets for future studies on immune treatment for osteosarcoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Immune-Related Genes Selected From Univariate Cox Regression Analysis
HR indicates hazard ratio.
Figure 2.
Figure 2.. Clinical Outcomes Based on Risk Score
IRG indicates immune-related gene.
Figure 3.
Figure 3.. Estimation of 1-Year Overall Survival in Patients With Osteosarcoma
AUC indicates area under the receiver operating curve; HR, hazard ratio.
Figure 4.
Figure 4.. Immunocyte Infiltration
Dots indicate individual data points; line, trend.
See this image and copyright information in PMC

References

    1. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029-3035. doi:10.1200/JCO.2014.59.4895 - DOI - PMC - PubMed
    1. Durnali A, Alkis N, Cangur S, et al. . Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30(3):624. doi:10.1007/s12032-013-0624-6 - DOI - PubMed
    1. Bielack SS, Kempf-Bielack B, Delling G, et al. . Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776-790. doi:10.1200/JCO.2002.20.3.776 - DOI - PubMed
    1. Heymann MF, Lézot F, Heymann D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell Immunol. 2019;343:103711. doi:10.1016/j.cellimm.2017.10.011 - DOI - PubMed
    1. Lettieri CK, Appel N, Labban N, Lussier DM, Blattman JN, Hingorani P. Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy. 2016;8(10):1233-1244. doi:10.2217/imt-2016-0048 - DOI - PubMed

Publication types